A prominent example is the panel of genetic makers, including RAS mutations, BRAF V600E mutation, RET/PTC and PAX8/PPARγ rearrangements, which, in a single-center unblinded study, yielded increased diagnostic sensitivities for thyroid cancer in the indeterminate cytological setting to 88 % for AUS and 87 % for FN [10]. The gene discussed is BRAF; the disease is thyroid cancer.